MAR 02, 2021 5:00 AM PST

Another Trick up Tumors' Sleeves Exposed

WRITTEN BY: Tara Fernandez

Tumors have sneaky strategies for establishing themselves within healthy tissues, flourishing in plain sight of circulating immune cells. Understanding the molecular basis of how cancer does this can help researchers identify potential flaws in tumors' game, to improve the aim on therapeutic targets.

A team of immunologists at St. Jude Children's Research Hospital have uncovered one of these missing pieces in an article published in Nature. Here, they describe how tumors barricade themselves behind activated regulatory T cells (Tregs), creating a signal to other immune cells to put their weapons down. Tregs are specialized lymphocytes that balance immune-mediated inflammation and prevent the body from launching attacks on its own tissues.

The researchers found a mechanism for controlling Tregs unique to the tumor, making it an attractive therapeutic target. This pathway is an excellent starting point for creating drugs that selectively disarm tumor-associated Tregs, allowing immune cells to infiltrate and eliminate the malignant cells.

"There has certainly been a great deal of interest in targeting regulatory T cells for cancer therapy because they are central to keeping the immune system in check in tumors," said author of the paper, Hongbo Chi. "But the risk of such targeting is possibly inducing autoimmune disease because these T cells are crucial to balancing the body's immune response.”

According to Chi, the study’s findings are particularly exciting as tumors’ pathways to reprogram Tregs are entirely independent. "Thus, we believe there is the potential for inhibiting regulatory T-cell activation in tumors to unleash effective antitumor immune responses without triggering autoimmune toxicity."

Blocking T reg activation in tumors has the potential to improve the effectiveness of existing immunotherapies, which don’t always work well for all cancer patients.

"Anti-PD-1 therapy currently works in only about 20% of cancer patients, although when it works, the response is durable in those cases," explained Chi. "Many pediatric cancers are not responsive to anti-PD-1. Our experiments showed that blocking this lipid pathway had quite a remarkable effect in sensitizing mice to the therapy.”

Follow-up studies to map these tumor-Treg interactions in more detail are in the cards, said Chi. 

"While we still have a long research path ahead of us, these findings suggest that if we can develop drugs to control this context-specific regulatory T cell pathway in cancer patients, we can make them even more responsive to immunological checkpoint therapies."

 

 

Sources: St. Jude’s Children’s Hospital, Nature.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUN 28, 2021
Microbiology
Small Clinical Trial Suggests New Edible Cholera Vaccine Is Safe
JUN 28, 2021
Small Clinical Trial Suggests New Edible Cholera Vaccine Is Safe
According to WHO there have been six cholera pandemics since the pathogen emerged from the Ganges river delta sometime i ...
JUL 15, 2021
Immunology
Your Immune System Can't Deal With All the Plastic You're Eating
JUL 15, 2021
Your Immune System Can't Deal With All the Plastic You're Eating
Microplastics—tiny fragments of plastic, less than five millimeters in diameter—pollute our environment and, ...
AUG 10, 2021
Immunology
A Tapeworm Drug as a COVID Antiviral?
AUG 10, 2021
A Tapeworm Drug as a COVID Antiviral?
A study by researchers at the Scripps Research Institute looking into potential COVID-19 medications has revealed a surp ...
SEP 12, 2021
Coronavirus
Real-World, Post-Delta COVID-19 Vaccine Data & Potential Treatment
SEP 12, 2021
Real-World, Post-Delta COVID-19 Vaccine Data & Potential Treatment
New research may have identified a potential treatment or preventive medication for SARS-CoV-2 and other viral infection ...
OCT 07, 2021
Immunology
A 3D-Printed COVID Vaccine Patch?
OCT 07, 2021
A 3D-Printed COVID Vaccine Patch?
Even the bravest souls can get a little nervous when it comes to rolling up their sleeves and getting a shot. Aichmophob ...
OCT 04, 2021
Health & Medicine
Guillain-Barre Syndrome After COVID-19 Infection
OCT 04, 2021
Guillain-Barre Syndrome After COVID-19 Infection
Researchers with the International GBS Outcome Study (IGOS) investigated newly-diagnosed GBS patients from the beginning ...
Loading Comments...